Dysport / Azzalure

Record type

Source-linked family profile

Recorded maker

Galderma (licensed from Ipsen)

Classification

Neuromodulator

Material identity

abobotulinumtoxinA

Snapshot date

14 August 2026

Manufacturer and category are catalogue fields. They are not, by themselves, a regulatory classification or verification of the exact marketed presentation.

Names and markets

Aliases in this profile

• Dysport

  International brand name

• Azzalure

  Aesthetic brand name in European markets

Alias grouping supports discovery. It does not claim that regional products, labels, units, formulations, or authorised uses are interchangeable.

Product names and regulatory context do not travel automatically between countries. Each row below is limited to its named source market.

• Azzalure

  Galderma · Neuromodulator

  →

1. Manufacturer

   1. Azzalure

   Galderma · European Union / international

   Open source ↗

   Supports: Azzalure identity and its naming relationship with Dysport in aesthetic markets.

2. Approved label

   2. Azzalure 125 Speywood units — Summary of Product Characteristics

   electronic Medicines Compendium · United Kingdom

   Open source ↗

   Supports: Current UK prescribing-information context for the named product presentation.

3. Approved label

   3. DYSPORT — United States drug label

   U.S. National Library of Medicine (DailyMed) · United States

   Open source ↗

   Supports: The United States DYSPORT identity, Galderma labeler context, and abobotulinumtoxinA naming.

1. 1

   Market-scoped names

   Dysport and Azzalure are separately documented names within the Galderma / Ipsen product family.

   Scope: Discovery relationship only; jurisdictional presentation and unit differences remain explicit.

   Evidence: AzzalureEvidence: Azzalure 125 Speywood units — Summary of Product CharacteristicsEvidence: DYSPORT — United States drug label
2. 2

   Material / active name

   The US label uses abobotulinumtoxinA, while the UK SmPC uses botulinum toxin type A and presentation-specific Speywood units.

   Scope: Terminology is reported from each source without a conversion claim.

   Evidence: Azzalure 125 Speywood units — Summary of Product CharacteristicsEvidence: DYSPORT — United States drug label

Use boundary

What this record does not establish

• Regulatory statusOnly within a source's named jurisdiction; family-profile review does not establish status elsewhere.
• Authenticity or supply chainA catalogue name cannot authenticate an individual box, lot, or seller.
• Clinical suitabilityNo product selection, patient assessment, dose, protocol, or injection technique is provided.
• Availability or equivalenceNames, formulations, units, and presentations can vary by market and over time.